Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL

Abstract : High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment.
Type de document :
Article dans une revue
Best Practice and Research: Clinical Haematology, Elsevier, 2011, 24 (2), pp.257-270. 〈10.1016〉
Liste complète des métadonnées

https://hal-ens-lyon.archives-ouvertes.fr/ensl-00808492
Contributeur : Agnès Ganivet <>
Soumis le : vendredi 5 avril 2013 - 15:17:38
Dernière modification le : vendredi 9 février 2018 - 01:07:01

Identifiants

  • HAL Id : ensl-00808492, version 1
  • DOI : 10.1016

Collections

Citation

Emmanuel Bachy, Gilles Salles. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Practice and Research: Clinical Haematology, Elsevier, 2011, 24 (2), pp.257-270. 〈10.1016〉. 〈ensl-00808492〉

Partager

Métriques

Consultations de la notice

88